AZ chief: Emerging markets are tougher than you think

AstraZeneca ($AZN) CEO David Brennan (photo) talks emerging markets, external collaborations and townhall meetings in a Q&A with Roger Crockett. And, extending the current prefence for bolt-on M&A, Brennan reminds us that he's "not a fan" of megamergers. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.